Low valuation, plenty of cash, accepted NDA, strong partner, reduces trips to the hospital and injections, lowers cost, improves QOL, similar safety and efficacy, large market. Only weakness and it's significant, AFFY has one shot on goal. This smells of an acquisition. Hello!!! or hellooooo for you Seinfeld fans.